Research and Markets: Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Pipeline Insights 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/m7nzhr/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )-Pipeline Insights" report to their offering.

Summary

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Pipeline Insights provides the in-depth analysis of the pipeline assets across the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Pipeline Insights Report covers the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome).

Scope

- The report provides a Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Landscape across the globe

- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information

- Coverage of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

- The report reviews key players involved in the therapeutics development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and also provide company profiling

- Pipeline products coverage based on various stages of development from NDA filings to discovery.

- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

For more information visit http://www.researchandmarkets.com/research/m7nzhr/mucopolysaccharido

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals